keyword
MENU ▼
Read by QxMD icon Read
search

Cancer, clinical research, oncology,

keyword
https://www.readbyqxmd.com/read/29776586/-the-role-and-use-of-patient-reported-outcomes-in-the-management-of-cancer-patients
#1
REVIEW
Patricia Marino, Marie Bannier, Jean-François Moulin, Gwenaëlle Gravis
Therapeutic innovations in the field of oncology allow to manage cancer as a chronic illness with treatments being administered over prolonged periods of time. In this context, it is now acknowledged that it is important to complete the assessment of benefit based on purely clinical endpoints using outcome measurement evaluated by patients themselves. The Patient reported outcome (PRO) concept has then emerged and there is an increasing interest in using the PROs as an indicator of the benefit of new therapeutic strategies...
May 15, 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/29770305/the-prostate-cancer-focal-therapy
#2
REVIEW
Filippo Pesapane, Francesca Patella, Enrico Maria Fumarola, Edoardo Zanchetta, Chiara Floridi, Gianpaolo Carrafiello, Chloë Standaert
Despite prostate cancer (PCa) is the leading form of non-cutaneous cancer in men, most patients with PCa die with disease rather than of the disease. Therefore, the risk of overtreatment should be considered by clinicians who have to distinguish between patients with high risk PCa (who would benefit from radical treatment) and patients who may be managed more conservatively, such as through active surveillance or emerging focal therapy (FT). The aim of FT is to eradicate clinically significant disease while protecting key genito-urinary structures and function from injury...
April 2018: Gland Surgery
https://www.readbyqxmd.com/read/29767345/metastatic-breast-cancer-collateral-damage-project-mbccd-scale-development-and-preliminary-results-of-the-survey-of-health-impact-needs-and-experiences-shine
#3
Timothy J Williamson, Susan M Love, Jessica N Clague DeHart, Alexandra Jorge-Miller, Leah Eshraghi, Heather Cooper Ortner, Annette L Stanton
PURPOSE: Until recently, people with metastatic breast cancer (MBC) had a very poor prognosis. New treatment approaches have prolonged the time that people with MBC live, but their quality of life has received less attention. Consequently, the needs and concerns across financial, vocational, psychological, social, and physical domains in MBC patients are poorly understood-particularly regarding the collateral damage or longer-term, life-altering impacts of MBC and its treatments. This study's aims were to characterize MBC-related collateral damage, identify groups most likely to experience collateral damage, and examine its associations with psychological health, illness management, and health behaviors...
May 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29766260/supportive-care-priorities-of-low-income-latina-breast-cancer-survivors
#4
Alix G Sleight, Kathleen Doyle Lyons, Cheryl Vigen, Heather Macdonald, Florence Clark
PURPOSE: This study investigated the supportive care needs of a sample of low-income Latina breast cancer survivors. METHODS: Ninety-nine Spanish-speaking breast cancer survivors who self-identified as Latina and reported an income below the US Census Bureau low-income threshold were recruited from the oncology clinic of a major public safety net hospital. Eligible participants completed the supportive care needs survey (SCNS-SF34) and a demographic questionnaire...
May 16, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29764186/patterns-of-symptom-control-and-palliative-care-focused-original-research-articles-in-the-international-journal-of-radiation-oncology-biology-physics-and-the-radiotherapy-and-oncology-journal-2005-2014
#5
Diana D Shi, Julia DiGiovanni, Sonia Skamene, Sarah Noveroske Philbrick, Yanbing Wang, Elizabeth A Barnes, Edward Chow, Adam Sullivan, Tracy A Balboni
BACKGROUND: A significant portion of radiation treatment (30-40%) is delivered with palliative intent. Given the frequency of palliative care (PC) in radiation oncology, we determined the patterns of research focusing on symptom control and palliative care (SCPC) in two prominent radiation oncology journals from 2005-2014. METHODS: Original research manuscripts published from 2005-2014 in the International Journal of Radiation Oncology *Biology* Physics (Red Journal) and the Radiotherapy and Oncology Journal (Green Journal) were reviewed to categorize articles as PC and/or SCPC...
April 2018: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29757235/clinically-applicable-inhibitors-impacting-genome-stability
#6
REVIEW
Anu Prakash, Juan F Garcia-Moreno, James A L Brown, Emer Bourke
Advances in technology have facilitated the molecular profiling (genomic and transcriptomic) of tumours, and has led to improved stratification of patients and the individualisation of treatment regimes. To fully realize the potential of truly personalised treatment options, we need targeted therapies that precisely disrupt the compensatory pathways identified by profiling which allow tumours to survive or gain resistance to treatments. Here, we discuss recent advances in novel therapies that impact the genome (chromosomes and chromatin), pathways targeted and the stage of the pathways targeted...
May 13, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29756367/oral-cancer-involving-masticator-space-t4b-review-of-literature-and-future-directions
#7
REVIEW
Nirav P Trivedi
The oral cancer with masticator-space involvement is classified as T4b disease. The limited data suggest that the masticator space is a complex anatomic area and tumors with varying degrees of infiltration may have different oncologic outcomes. It is not advisable to group all T4b tumors as one and consider them for palliative-intent treatment. A group of patients with limited spread (infra-notch) has potential for good outcome. These cancers can be considered for downstaging to T4a classification based on best available data and clinical considerations...
May 13, 2018: Head & Neck
https://www.readbyqxmd.com/read/29756123/the-quality-of-total-mesorectal-excision-specimen-a-review-of-its-macroscopic-assessment-and-prognostic-significance
#8
Shi-Bo Song, Guo-Ju Wu, Hong-Da Pan, Hua Yang, Mao-Lin Hu, Qiang Li, Qiu-Xia Yan, Gang Xiao
As a surgical procedure which could significantly lower the recurrence rate of cancers, total mesorectal excision (TME) has been the gold standard for middle and lower rectal cancer treatment. However, previous studies have shown that the procedure did not achieve the ideal theoretical local recurrence rates of rectal cancers. Some researchers pointed out it was very likely that not all so-called TME treatments completely removed the mesorectum, implying that some of these TME surgical treatments failed to meet oncological quality standards...
March 2018: Chronic Diseases and Translational Medicine
https://www.readbyqxmd.com/read/29754777/international-validation-of-the-consensus-immunoscore-for-the-classification-of-colon-cancer-a-prognostic-and-accuracy-study
#9
Franck Pagès, Bernhard Mlecnik, Florence Marliot, Gabriela Bindea, Fang-Shu Ou, Carlo Bifulco, Alessandro Lugli, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Y Wang, P Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia K Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Bénédicte Buttard, Mihaela Angelova, Angela Vasaturo, Pauline Maby, Sarah E Church, Helen K Angell, Lucie Lafontaine, Daniela Bruni, Carine El Sissy, Nacilla Haicheur, Amos Kirilovsky, Anne Berger, Christine Lagorce, Jeffrey P Meyers, Christopher Paustian, Zipei Feng, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Kyogo Itoh, Prabhu S Patel, Hemangini H Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M Marincola, Paolo A Ascierto, Daniel J Sargent, Bernard A Fox, Jérôme Galon
BACKGROUND: The estimation of risk of recurrence for patients with colon carcinoma must be improved. A robust immune score quantification is needed to introduce immune parameters into cancer classification. The aim of the study was to assess the prognostic value of total tumour-infiltrating T-cell counts and cytotoxic tumour-infiltrating T-cells counts with the consensus Immunoscore assay in patients with stage I-III colon cancer. METHODS: An international consortium of 14 centres in 13 countries, led by the Society for Immunotherapy of Cancer, assessed the Immunoscore assay in patients with TNM stage I-III colon cancer...
May 10, 2018: Lancet
https://www.readbyqxmd.com/read/29753700/spectrum-and-prevalence-of-genetic-predisposition-in-medulloblastoma-a-retrospective-genetic-study-and-prospective-validation-in-a-clinical-trial-cohort
#10
Sebastian M Waszak, Paul A Northcott, Ivo Buchhalter, Giles W Robinson, Christian Sutter, Susanne Groebner, Kerstin B Grund, Laurence Brugières, David T W Jones, Kristian W Pajtler, A Sorana Morrissy, Marcel Kool, Dominik Sturm, Lukas Chavez, Aurelie Ernst, Sebastian Brabetz, Michael Hain, Thomas Zichner, Maia Segura-Wang, Joachim Weischenfeldt, Tobias Rausch, Balca R Mardin, Xin Zhou, Cristina Baciu, Christian Lawerenz, Jennifer A Chan, Pascale Varlet, Lea Guerrini-Rousseau, Daniel W Fults, Wiesława Grajkowska, Peter Hauser, Nada Jabado, Young-Shin Ra, Karel Zitterbart, Suyash S Shringarpure, Francisco M De La Vega, Carlos D Bustamante, Ho-Keung Ng, Arie Perry, Tobey J MacDonald, Pablo Hernáiz Driever, Anne E Bendel, Daniel C Bowers, Geoffrey McCowage, Murali M Chintagumpala, Richard Cohn, Timothy Hassall, Gudrun Fleischhack, Tone Eggen, Finn Wesenberg, Maria Feychting, Birgitta Lannering, Joachim Schüz, Christoffer Johansen, Tina V Andersen, Martin Röösli, Claudia E Kuehni, Michael Grotzer, Kristina Kjaerheim, Camelia M Monoranu, Tenley C Archer, Elizabeth Duke, Scott L Pomeroy, Redmond Shelagh, Stephan Frank, David Sumerauer, Wolfram Scheurlen, Marina V Ryzhova, Till Milde, Christian P Kratz, David Samuel, Jinghui Zhang, David A Solomon, Marco Marra, Roland Eils, Claus R Bartram, Katja von Hoff, Stefan Rutkowski, Vijay Ramaswamy, Richard J Gilbertson, Andrey Korshunov, Michael D Taylor, Peter Lichter, David Malkin, Amar Gajjar, Jan O Korbel, Stefan M Pfister
BACKGROUND: Medulloblastoma is associated with rare hereditary cancer predisposition syndromes; however, consensus medulloblastoma predisposition genes have not been defined and screening guidelines for genetic counselling and testing for paediatric patients are not available. We aimed to assess and define these genes to provide evidence for future screening guidelines. METHODS: In this international, multicentre study, we analysed patients with medulloblastoma from retrospective cohorts (International Cancer Genome Consortium [ICGC] PedBrain, Medulloblastoma Advanced Genomics International Consortium [MAGIC], and the CEFALO series) and from prospective cohorts from four clinical studies (SJMB03, SJMB12, SJYC07, and I-HIT-MED)...
May 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29749682/psycho-oncology-overview-obstacles-and-opportunities
#11
Jimmie C Holland
Worldwide, psychological and social issues in cancer were not the subject of scientific inquiry until the past two decades. Since then, a new subspecialty of oncology has evolved, psycho-oncology. It addresses two dimensions of cancer: the emotional responses of patients at all stages of disease, as well as their families and caretakers (psychosocial); and the pyschological, social and behavioral factors that may influence cancer morbidity and mortality (psychobiological). Obstacles to development have been the facts of small numbers of clinicians and investigators worldwide and the few valid assessment instruments and research methods available to the biomedical community...
May 2018: Psycho-oncology
https://www.readbyqxmd.com/read/29746226/medical-oncologists-beliefs-practices-and-knowledge-regarding-marijuana-used-therapeutically-a-nationally-representative-survey-study
#12
Ilana M Braun, Alexi Wright, John Peteet, Fremonta L Meyer, David P Yuppa, Dragana Bolcic-Jankovic, Jessica LeBlanc, Yuchiao Chang, Liyang Yu, Manan M Nayak, James A Tulsky, Joji Suzuki, Lida Nabati, Eric G Campbell
Background Although almost every state medical marijuana (MM) law identifies cancer as a qualifying condition, little research supports MM's use in oncology. We hypothesized that the discrepancy between these laws and the scientific evidence base poses clinical challenges for oncologists. Oncologists' beliefs, knowledge, and practices regarding MM were examined in this study. Methods In November 2016, we mailed a survey on MM to a nationally-representative, random sample of 400 medical oncologists. Main outcome measures included whether oncologists reported discussing MM with patients, recommended MM clinically in the past year, or felt sufficiently informed to make such recommendations...
May 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29745076/ten-years-of-using-adjuvant-trastuzumab-in-breast-cancer-in-serbia-single-institution-experience
#13
Ana Cvetanovic, Sladjana Filipovic, Nikola Zivkovic, Lazar Popovic, Milos Kostic, Miodrag Djordjevic, Aleksandar Karanikolic, Dane Krtinic
PURPOSE: The purpose of this study was to determinate disease-free interval (DFI) and overall survival (OS) in HER2-positive breast cancer patients who received adjuvant trastuzumab at the University Clinic of Nis, Serbia, and to investigate the influence of clinicopathological and biological characteristics of the tumor on prognosis. The second aim was to determinate the most frequent cause for the treatment discontinuation, recurrence rate, as well as the site of most common localization of the first recurrence of disease...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29743988/molecular-mechanisms-underlying-curcumin-mediated-therapeutic-effects-in-type-2-diabetes-and-cancer
#14
REVIEW
Marzena Wojcik, Michal Krawczyk, Pawel Wojcik, Katarzyna Cypryk, Lucyna Alicja Wozniak
The growing prevalence of age-related diseases, especially type 2 diabetes mellitus (T2DM) and cancer, has become global health and economic problems. Due to multifactorial nature of both diseases, their pathophysiology is not completely understood so far. Compelling evidence indicates that increased oxidative stress, resulting from an imbalance between production of reactive oxygen species (ROS) and their clearance by antioxidant defense mechanisms, as well as the proinflammatory state contributes to the development and progression of the diseases...
2018: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/29742281/analyzing-the-clinical-actionability-of-germline-pharmacogenomic-findings-in-oncology
#15
Rebecca Wellmann, Brittany A Borden, Keith Danahey, Rita Nanda, Blase N Polite, Walter M Stadler, Mark J Ratain, Peter H O'Donnell
BACKGROUND: Germline and tumor pharmacogenomics impact drug responses, but germline markers less commonly guide oncology prescribing. The authors hypothesized that a critical number of clinically actionable germline pharmacogenomic associations exist, representing clinical implementation opportunities. METHODS: In total, 125 oncology drugs were analyzed for positive germline pharmacogenomic associations in journals with impact factors ≥5. Studies were assessed for design and genotyping quality, clinically relevant outcomes, statistical rigor, and evidence of drug-gene effects...
May 9, 2018: Cancer
https://www.readbyqxmd.com/read/29741547/microenvironmental-influence-on-microtumour-infiltration-patterns-3d-mathematical-modelling-supported-by-in-vitro-studies
#16
Emmanuel Luján, Daniela Soto, María S Rosito, Alejandro Soba, Liliana N Guerra, Juan C Calvo, Guillermo Marshall, Cecilia Suárez
Mathematical modelling approaches have become increasingly abundant in cancer research. Tumour infiltration extent and its spatial organization depend both on the tumour type and stage and on the bio-physicochemical characteristics of the microenvironment. This sets a complex scenario that often requires a multidisciplinary and individually adjusted approach. The ultimate goal of this work is to present an experimental/numerical combined method for the development of a three-dimensional mathematical model with the ability to reproduce the growth and infiltration patterns of a given avascular microtumour in response to different microenvironmental conditions...
May 9, 2018: Integrative Biology: Quantitative Biosciences From Nano to Macro
https://www.readbyqxmd.com/read/29740588/is-there-any-role-for-d3-lymphadenectomy-in-gastric-cancer
#17
Gerassimos N Douridas, Stefanos K Pierrakakis
Although D2 constitutes the level of lymph node dissection which most surgical associations endorse in their treatment guidelines for gastric cancer more extended D3 dissection has also been attempted to improve oncologic outcomes. Existing literature pertinent with the provisional therapeutic impact of D3 lymphadenectomy in advanced gastric cancer is studied in this mini review. Seven non-randomized comparisons, three randomized trials and five meta-analyses, almost exclusively of Asian origin, were identified and examined...
2018: Frontiers in Surgery
https://www.readbyqxmd.com/read/29739897/cluster-analysis-demonstrates-the-need-to-individualize-care-for-cancer-survivors
#18
Belle H de Rooij, Elyse R Park, Giselle K Perez, Julia Rabin, Katharine M Quain, Don S Dizon, Kathryn E Post, Garrett M Chinn, Allison L McDonough, Rachel B Jimenez, Lonneke V van de Poll-Franse, Jeffrey Peppercorn
BACKGROUND: In efforts to inform clinical screening and development of survivorship care services, we sought to characterize patterns of health care needs among cancer survivors by (a) identifying and characterizing subgroups based on self-reported health care needs and (b) assessing sociodemographic, clinical, and psychosocial factors associated with these subgroups. METHODS: We conducted a cross-sectional self-administered survey among patients presenting for routine follow-up care for early-stage cancer at our academic medical center...
May 8, 2018: Oncologist
https://www.readbyqxmd.com/read/29733728/strategies-for-clinical-implementation-precision-oncology-at-three-distinct-institutions
#19
Lincoln D Nadauld, James M Ford, Daryl Pritchard, Thomas Brown
Despite rapid advances in molecular diagnostics and targeted therapeutics, the adoption of precision medicine into clinical oncology workflows has been slow. Questions about clinical utility, inconsistent reimbursement for molecular diagnostics, and limited access to targeted therapies are some of the major hurdles that have hampered clinical adoption. Despite these challenges, providers have invested in precision medicine programs in an ongoing search for innovative care models to deliver improved patient outcomes and achieve economic gains...
May 2018: Health Affairs
https://www.readbyqxmd.com/read/29733723/real-world-evidence-in-support-of-precision-medicine-clinico-genomic-cancer-data-as-a-case-study
#20
Vineeta Agarwala, Sean Khozin, Gaurav Singal, Claire O'Connell, Deborah Kuk, Gerald Li, Anala Gossai, Vincent Miller, Amy P Abernethy
The majority of US adult cancer patients today are diagnosed and treated outside the context of any clinical trial (that is, in the real world). Although these patients are not part of a research study, their clinical data are still recorded. Indeed, data captured in electronic health records form an ever-growing, rich digital repository of longitudinal patient experiences, treatments, and outcomes. Likewise, genomic data from tumor molecular profiling are increasingly guiding oncology care. Linking real-world clinical and genomic data, as well as information from other co-occurring data sets, could create study populations that provide generalizable evidence for precision medicine interventions...
May 2018: Health Affairs
keyword
keyword
11651
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"